{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:27Z","timestamp":1790666967172,"version":"4.1.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Steroid-resistant nephrotic syndrome (SRNS) remains a challenge for paediatric nephrologists. SRNS is viewed as a heterogeneous disease entity including immune-based and monogenic aetiologies. Because SRNS is rare, treatment strategies are individualized and vary among centres of expertise. Calcineurin inhibitors (CNI) have been effectively used to induce remission in patients with immune-based SRNS; however, there is still no consensus on treating children who become either CNI-dependent or CNI-resistant. Rituximab is a steroid-sparing agent for patients with steroid-sensitive nephrotic syndrome, but its efficacy in SRNS is controversial. Recently, several novel monoclonal antibodies are emerging as treatment option, but their efficacy remains to be seen. Non-immune therapies, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have been proven efficacious in children with SRNS and are recommended as adjuvant agents. This review summarizes and discusses our current understandings in treating children with idiopathic SRNS.<\/jats:p>","DOI":"10.1007\/s00467-020-04476-9","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T11:02:56Z","timestamp":1582282976000},"page":"747-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Current understandings in treating children with steroid-resistant nephrotic syndrome"],"prefix":"10.1007","volume":"36","author":[{"given":"Jiwon M.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-675X","authenticated-orcid":false,"given":"Jun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"4476_CR1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629\u2013639","journal-title":"Lancet"},{"key":"4476_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12882-019-1233-1","volume":"20","author":"I Franke","year":"2019","unstructured":"Franke I, Aydin M, Kurylowicz L, Lopez CEL, Ganschow R, Lentze MJ, Born M (2019) Clinical course & management of childhood nephrotic syndrome in Germany: a large epidemiological ESPED study. BMC Nephrol 20:45","journal-title":"BMC Nephrol"},{"key":"4476_CR3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10157-017-1433-6","volume":"22","author":"I Franke","year":"2018","unstructured":"Franke I, Aydin M, Llamas Lopez CE, Kurylowicz L, Ganschow R, Lentze M, Born M (2018) The incidence of the nephrotic syndrome in childhood in Germany. Clin Exp Nephrol 22:126\u2013132","journal-title":"Clin Exp Nephrol"},{"key":"4476_CR4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00467-016-3509-z","volume":"31","author":"C Dossier","year":"2016","unstructured":"Dossier C, Lapidus N, Bayer F, Sellier-Leclerc AL, Boyer O, de Pontual L, May A, Nathanson S, Orzechowski C, Simon T, Carrat F, Deschenes G (2016) Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatr Nephrol 31:2299\u20132308","journal-title":"Pediatr Nephrol"},{"key":"4476_CR5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ekir.2019.01.019","volume":"4","author":"L Nandlal","year":"2019","unstructured":"Nandlal L, Naicker T, Bhimma R (2019) Nephrotic syndrome in South African children: changing perspectives in the new millennium. Kidney Int Rep 4:522\u2013534","journal-title":"Kidney Int Rep"},{"key":"4476_CR6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10157-016-1319-z","volume":"21","author":"K Kikunaga","year":"2017","unstructured":"Kikunaga K, Ishikura K, Terano C, Sato M, Komaki F, Hamasaki Y, Sasaki S, Iijima K, Yoshikawa N, Nakanishi K, Nakazato H, Matsuyama T, Ando T, Ito S, Honda M, Japanese Pediatric Survey Holding Information of NEphrotic syndrome (JP-SHINE) study of the Japanese Study Group of Renal Disease in Children (2017) High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study). Clin Exp Nephrol 21:651\u2013657","journal-title":"Clin Exp Nephrol"},{"key":"4476_CR7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","volume":"2","author":"K Tullus","year":"2018","unstructured":"Tullus K, Webb H, Bagga A (2018) Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health 2:880\u2013890","journal-title":"Lancet Child Adolesc Health"},{"key":"4476_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374","journal-title":"Lancet"},{"key":"4476_CR9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fped.2018.00200","volume":"6","author":"A Trautmann","year":"2018","unstructured":"Trautmann A, Lipska-Zietkiewicz BS, Schaefer F (2018) Exploring the clinical and genetic spectrum of steroid resistant nephrotic syndrome: the PodoNet registry. Front Pediatr 6:200","journal-title":"Front Pediatr"},{"key":"4476_CR10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2215\/CJN.04120417","volume":"13","author":"JK Warejko","year":"2018","unstructured":"Warejko JK, Tan W, Daga A, Schapiro D, Lawson JA, Shril S, Lovric S, Ashraf S, Rao J, Hermle T, Jobst-Schwan T, Widmeier E, Majmundar AJ, Schneider R, Gee HY, Schmidt JM, Vivante A, van der Ven AT, Ityel H, Chen J, Sadowski CE, Kohl S, Pabst WL, Nakayama M, Somers MJG, Rodig NM, Daouk G, Baum M, Stein DR, Ferguson MA, Traum AZ, Soliman NA, Kari JA, El Desoky S, Fathy H, Zenker M, Bakkaloglu SA, Muller D, Noyan A, Ozaltin F, Cadnapaphornchai MA, Hashmi S, Hopcian J, Kopp JB, Benador N, Bockenhauer D, Bogdanovic R, Stajic N, Chernin G, Ettenger R, Fehrenbach H, Kemper M, Munarriz RL, Podracka L, Buscher R, Serdaroglu E, Tasic V, Mane S, Lifton RP, Braun DA, Hildebrandt F (2018) Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 13:53\u201362","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR11","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1681\/ASN.2016101121","volume":"28","author":"A Trautmann","year":"2017","unstructured":"Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS, Bodria M, Ozaltin F, Emma F, Anarat A, Melk A, Azocar M, Oh J, Saeed B, Gheisari A, Caliskan S, Gellermann J, Higuita LMS, Jankauskiene A, Drozdz D, Mir S, Balat A, Szczepanska M, Paripovic D, Zurowska A, Bogdanovic R, Yilmaz A, Ranchin B, Baskin E, Erdogan O, Remuzzi G, Firszt-Adamczyk A, Kuzma-Mroczkowska E, Litwin M, Murer L, Tkaczyk M, Jardim H, Wasilewska A, Printza N, Fidan K, Simkova E, Borzecka H, Staude H, Hees K, Schaefer F, PodoNet Consortium (2017) Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 28:3055\u20133065","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00467-012-2304-8","volume":"28","author":"RM Lombel","year":"2013","unstructured":"Lombel RM, Hodson EM, Gipson DS, Kidney Disease: Improving Global Outcomes (2013) Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 28:409\u2013414","journal-title":"Pediatr Nephrol"},{"key":"4476_CR13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00467-009-1138-5","volume":"24","author":"D Mekahli","year":"2009","unstructured":"Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, Van Damme-Lombaerts R, Palcoux JB, Cachat F, Lavocat MP, Bourdat-Michel G, Nobili F, Cochat P (2009) Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 24:1525\u20131532","journal-title":"Pediatr Nephrol"},{"key":"4476_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/PHMT.S100803","volume":"8","author":"N Nourbakhsh","year":"2017","unstructured":"Nourbakhsh N, Mak RH (2017) Steroid-resistant nephrotic syndrome: past and current perspectives. Pediatric Health Med Ther 8:29\u201337","journal-title":"Pediatric Health Med Ther"},{"key":"4476_CR15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41581-019-0217-5","volume":"15","author":"MA Saleem","year":"2019","unstructured":"Saleem MA (2019) Molecular stratification of idiopathic nephrotic syndrome. Nat Rev Nephrol 15:750\u2013765","journal-title":"Nat Rev Nephrol"},{"key":"4476_CR16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.kint.2016.10.013","volume":"91","author":"A Bierzynska","year":"2017","unstructured":"Bierzynska A, McCarthy HJ, Soderquest K, Sen ES, Colby E, Ding WY, Nabhan MM, Kerecuk L, Hegde S, Hughes D, Marks S, Feather S, Jones C, Webb NJ, Ognjanovic M, Christian M, Gilbert RD, Sinha MD, Lord GM, Simpson M, Koziell AB, Welsh GI, Saleem MA (2017) Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int 91:937\u2013947","journal-title":"Kidney Int"},{"key":"4476_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","volume":"11","author":"JS Sloka","year":"2005","unstructured":"Sloka JS, Stefanelli M (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 11:425\u2013432","journal-title":"Mult Scler"},{"key":"4476_CR18","unstructured":"The American Society of Health-System Pharmacists (2016) Methylprednisolone. Online Available at https:\/\/wwwdrugscom\/monograph\/methylprednisolonehtml - accessed December 2019"},{"key":"4476_CR19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000184308","volume":"46","author":"WR Griswold","year":"1987","unstructured":"Griswold WR, Tune BM, Reznik VM, Vazquez M, Prime DJ, Brock P, Mendoza SA (1987) Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents. Nephron 46:73\u201377","journal-title":"Nephron"},{"key":"4476_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00862503","volume":"4","author":"SA Mendoza","year":"1990","unstructured":"Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM (1990) Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 4:303\u2013307","journal-title":"Pediatr Nephrol"},{"key":"4476_CR21","first-page":"84","volume":"43","author":"BM Tune","year":"1995","unstructured":"Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84\u201388","journal-title":"Clin Nephrol"},{"key":"4476_CR22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s004670000494","volume":"16","author":"PD Yorgin","year":"2001","unstructured":"Yorgin PD, Krasher J, Al-Uzri AY (2001) Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol 16:245\u2013250","journal-title":"Pediatr Nephrol"},{"key":"4476_CR23","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s00467-004-1584-z","volume":"19","author":"K Mori","year":"2004","unstructured":"Mori K, Honda M, Ikeda M (2004) Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol 19:1232\u20131236","journal-title":"Pediatr Nephrol"},{"key":"4476_CR24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00467-015-3174-7","volume":"31","author":"A Inaba","year":"2016","unstructured":"Inaba A, Hamasaki Y, Ishikura K, Hamada R, Sakai T, Hataya H, Komaki F, Kaneko T, Mori M, Honda M (2016) Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children. Pediatr Nephrol 31:425\u2013434","journal-title":"Pediatr Nephrol"},{"key":"4476_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1681\/ASN.2007040452","volume":"19","author":"Hinkes B, Vlangos C, Heeringa S, Mucha B, Gbadegesin R, Liu J, Hasselbacher K, Ozaltin F, Hildebrandt F; APN Study Group","year":"2008","unstructured":"Hinkes B, Vlangos C, Heeringa S, Mucha B, Gbadegesin R, Liu J, Hasselbacher K, Ozaltin F, Hildebrandt F; APN Study Group (2008) Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome. J Am Soc Nephrol 19:365\u2013371","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00467-016-3459-5","volume":"32","author":"S Dogra","year":"2017","unstructured":"Dogra S, Kaskel F (2017) Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology. Pediatr Nephrol 32:965\u2013974","journal-title":"Pediatr Nephrol"},{"key":"4476_CR27","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00467-015-3109-3","volume":"30","author":"I Klaassen","year":"2015","unstructured":"Klaassen I, Ozgoren B, Sadowski CE, Moller K, van Husen M, Lehnhardt A, Timmermann K, Freudenberg F, Helmchen U, Oh J, Kemper MJ (2015) Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible. Pediatr Nephrol 30:1477\u20131483","journal-title":"Pediatr Nephrol"},{"key":"4476_CR28","doi-asserted-by":"crossref","first-page":"73050","DOI":"10.18632\/oncotarget.20377","volume":"8","author":"S Li","year":"2017","unstructured":"Li S, Yang H, Guo P, Ao X, Wan J, Li Q, Tan L (2017) Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis. Oncotarget 8:73050\u201373062","journal-title":"Oncotarget"},{"key":"4476_CR29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.2012.238","volume":"82","author":"A Gulati","year":"2012","unstructured":"Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P, Bagga A (2012) Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 82:1130\u20131135","journal-title":"Kidney Int"},{"key":"4476_CR30","first-page":"CD003594","volume":"10","author":"EM Hodson","year":"2016","unstructured":"Hodson EM, Wong SC, Willis NS, Craig JC (2016) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 10:CD003594","journal-title":"Cochrane Database Syst Rev"},{"key":"4476_CR31","unstructured":"(2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139\u2013274"},{"key":"4476_CR32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","volume":"92","author":"A Sinha","year":"2017","unstructured":"Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A (2017) Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney Int 92:248\u2013257","journal-title":"Kidney Int"},{"key":"4476_CR33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/ijn.IJN_240_16","volume":"28","author":"N Prasad","year":"2018","unstructured":"Prasad N, Manjunath R, Rangaswamy D, Jaiswal A, Agarwal V, Bhadauria D, Kaul A, Sharma R, Gupta A (2018) Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: a prospective study. Indian J Nephrol 28:46\u201352","journal-title":"Indian J Nephrol"},{"key":"4476_CR34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","volume":"53","author":"S Choudhry","year":"2009","unstructured":"Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A (2009) Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 53:760\u2013769","journal-title":"Am J Kidney Dis"},{"key":"4476_CR35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0971-4065.107197","volume":"23","author":"A Sinha","year":"2013","unstructured":"Sinha A, Sharma A, Mehta A, Gupta R, Gulati A, Hari P, Dinda AK, Bagga A (2013) Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome. Indian J Nephrol 23:41\u201346","journal-title":"Indian J Nephrol"},{"key":"4476_CR36","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00467-017-3641-4","volume":"32","author":"Y Hamasaki","year":"2017","unstructured":"Hamasaki Y, Komaki F, Ishikura K, Hamada R, Sakai T, Hataya H, Ogata K, Ando T, Honda M (2017) Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment. Pediatr Nephrol 32:1383\u20131390","journal-title":"Pediatr Nephrol"},{"key":"4476_CR37","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1046\/j.1523-1755.2002.00303.x","volume":"61","author":"K Iijima","year":"2002","unstructured":"Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N (2002) Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61:1801\u20131805","journal-title":"Kidney Int"},{"key":"4476_CR38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s004670050044","volume":"14","author":"MG Seikaly","year":"2000","unstructured":"Seikaly MG, Prashner H, Nolde-Hurlbert B, Browne R (2000) Long-term clinical and pathological effects of cyclosporin in children with nephrosis. Pediatr Nephrol 14:214\u2013217","journal-title":"Pediatr Nephrol"},{"key":"4476_CR39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/adc.2005.080960","volume":"91","author":"S Fujinaga","year":"2006","unstructured":"Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y (2006) Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child 91:666\u2013670","journal-title":"Arch Dis Child"},{"key":"4476_CR40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/jclinpath-2011-200005","volume":"64","author":"JH Kim","year":"2011","unstructured":"Kim JH, Park SJ, Yoon SJ, Lim BJ, Jeong HJ, Lee JS, Kim PK, Shin JI (2011) Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. J Clin Pathol 64:516\u2013519","journal-title":"J Clin Pathol"},{"key":"4476_CR41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00467-018-4145-6","volume":"34","author":"S Fujinaga","year":"2019","unstructured":"Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y, Sakuraya K (2019) Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome. Pediatr Nephrol 34:353\u2013357","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 1","key":"4476_CR42","first-page":"S31","volume":"35","author":"P Niaudet","year":"1991","unstructured":"Niaudet P, Broyer M, Habib R (1991) Treatment of idiopathic nephrotic syndrome with cyclosporin a in children. Clin Nephrol 35(Suppl 1):S31\u2013S36","journal-title":"Clin Nephrol"},{"key":"4476_CR43","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00467-019-04343-2","volume":"34","author":"JD Delbet","year":"2019","unstructured":"Delbet JD, Aoun B, Buob D, Degheili J, Brocheriou I, Ulinski T (2019) Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34:2605\u20132608","journal-title":"Pediatr Nephrol"},{"key":"4476_CR44","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1600-6143.2004.00427.x","volume":"4","author":"MA Artz","year":"2004","unstructured":"Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Moons P, Borm G, Hilbrands LB (2004) Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 4:937\u2013945","journal-title":"Am J Transplant"},{"key":"4476_CR45","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","volume":"100","author":"BJ Nankivell","year":"2016","unstructured":"Nankivell BJ, P\u2019Ng CH, O\u2019Connell PJ, Chapman JR (2016) Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation 100:1723\u20131731","journal-title":"Transplantation"},{"key":"4476_CR46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00467-003-1095-3","volume":"18","author":"A Bajpai","year":"2003","unstructured":"Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN (2003) Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol 18:351\u2013356","journal-title":"Pediatr Nephrol"},{"key":"4476_CR47","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00467-008-0794-1","volume":"23","author":"C Plank","year":"2008","unstructured":"Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W, Arbeitsgemeinschaft fur Padiatrische Nephrologie (2008) Cyclosporin a is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. Pediatr Nephrol 23:1483\u20131493","journal-title":"Pediatr Nephrol"},{"key":"4476_CR48","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s004670050167","volume":"10","author":"P Tarshish","year":"1996","unstructured":"Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1996) Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the international study of kidney disease in children. Pediatr Nephrol 10:590\u2013593","journal-title":"Pediatr Nephrol"},{"key":"4476_CR49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s004670000523","volume":"16","author":"K Latta","year":"2001","unstructured":"Latta K, von Schnakenburg C, Ehrich JH (2001) A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16:271\u2013282","journal-title":"Pediatr Nephrol"},{"key":"4476_CR50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00467-003-1170-9","volume":"18","author":"U Vester","year":"2003","unstructured":"Vester U, Kranz B, Zimmermann S, Hoyer PF (2003) Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 18:661\u2013664","journal-title":"Pediatr Nephrol"},{"key":"4476_CR51","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1177\/0300060518782017","volume":"46","author":"Y Liu","year":"2018","unstructured":"Liu Y, Yang R, Yang C, Dong S, Zhu Y, Zhao M, Yuan F, Gui K (2018) Cyclophosphamide versus cyclosporine a therapy in steroid-resistant nephrotic syndrome: a retrospective study with a mean 5-year follow-up. J Int Med Res 46:4506\u20134517","journal-title":"J Int Med Res"},{"key":"4476_CR52","doi-asserted-by":"publisher","unstructured":"Lee JM, Kronbichler A, Shin JI, Oh J (2019) Review on long-term non-renal complications of childhood nephrotic syndrome. Acta Paediatr. https:\/\/doi.org\/10.1111\/apa.15035","DOI":"10.1111\/apa.15035"},{"key":"4476_CR53","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ki.2011.33","volume":"79","author":"H Trachtman","year":"2011","unstructured":"Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F (2011) A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79:1236\u20131243","journal-title":"Kidney Int"},{"key":"4476_CR54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00467-003-1314-y","volume":"19","author":"A Bagga","year":"2004","unstructured":"Bagga A, Mudigoudar BD, Hari P, Vasudev V (2004) Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 19:45\u201350","journal-title":"Pediatr Nephrol"},{"key":"4476_CR55","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","volume":"80","author":"DS Gipson","year":"2011","unstructured":"Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D\u2019Agati VD, Friedman AL (2011) Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80:868\u2013878","journal-title":"Kidney Int"},{"key":"4476_CR56","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00467-009-1375-7","volume":"25","author":"Z Li","year":"2010","unstructured":"Li Z, Duan C, He J, Wu T, Xun M, Zhang Y, Yin Y (2010) Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 25:883\u2013888","journal-title":"Pediatr Nephrol"},{"key":"4476_CR57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nep.12351","volume":"20","author":"B Wu","year":"2015","unstructured":"Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, Gu W, Shu Q, Du L (2015) Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing. Nephrology (Carlton) 20:18\u201324","journal-title":"Nephrology (Carlton)"},{"issue":"191\u2013197","key":"4476_CR58","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.jpeds.2018.01.008","volume":"197","author":"M Jellouli","year":"2018","unstructured":"Jellouli M, Charfi R, Maalej B, Mahfoud A, Trabelsi S, Gargah T (2018) Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: a systematic review. J Pediatr 197(191\u2013197):e191","journal-title":"J Pediatr"},{"key":"4476_CR59","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/20469047.2017.1374003","volume":"37","author":"ML Downie","year":"2017","unstructured":"Downie ML, Gallibois C, Parekh RS, Noone DG (2017) Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health 37:248\u2013258","journal-title":"Paediatr Int Child Health"},{"key":"4476_CR60","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMc063706","volume":"356","author":"A Bagga","year":"2007","unstructured":"Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356:2751\u20132752","journal-title":"N Engl J Med"},{"key":"4476_CR61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00467-018-4166-1","volume":"35","author":"K Kamei","year":"2020","unstructured":"Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K (2020) Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatr Nephrol 35:17\u201324","journal-title":"Pediatr Nephrol"},{"key":"4476_CR62","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00467-014-2765-z","volume":"29","author":"K Kamei","year":"2014","unstructured":"Kamei K, Okada M, Sato M, Fujimaru T, Ogura M, Nakayama M, Kaito H, Iijima K, Ito S (2014) Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol 29:1181\u20131187","journal-title":"Pediatr Nephrol"},{"key":"4476_CR63","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:1117\u20131124","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR64","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00467-017-3621-8","volume":"32","author":"CS Wang","year":"2017","unstructured":"Wang CS, Liverman RS, Garro R, George RP, Glumova A, Karp A, Jernigan S, Warshaw B (2017) Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol 32:835\u2013841","journal-title":"Pediatr Nephrol"},{"key":"4476_CR65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00467-016-3498-y","volume":"32","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, Ghiggeri G (2017) Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol 32:181\u2013184","journal-title":"Pediatr Nephrol"},{"key":"4476_CR66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00467-017-3866-2","volume":"33","author":"S Fujinaga","year":"2018","unstructured":"Fujinaga S, Sakuraya K (2018) Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies. Pediatr Nephrol 33:527\u2013528","journal-title":"Pediatr Nephrol"},{"key":"4476_CR67","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMc1308488","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu B (2014) Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 370:1268\u20131270","journal-title":"N Engl J Med"},{"key":"4476_CR68","doi-asserted-by":"publisher","unstructured":"Bonanni A, Rossi R, Murtas C (2015) Ghiggeri GM (2015) low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2015-210208","DOI":"10.1136\/bcr-2015-210208"},{"key":"4476_CR69","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"CC Yu","year":"2013","unstructured":"Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369:2416\u20132423","journal-title":"N Engl J Med"},{"key":"4476_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000454947","volume":"7","author":"T Kristensen","year":"2017","unstructured":"Kristensen T, Ivarsen P, Povlsen JV (2017) Unsuccessful treatment with abatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation. Case Rep Nephrol Dial 7:1\u20135","journal-title":"Case Rep Nephrol Dial"},{"key":"4476_CR71","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.ajkd.2009.08.019","volume":"55","author":"MS Joy","year":"2010","unstructured":"Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H (2010) Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (novel therapies for resistant FSGS) study group. Am J Kidney Dis 55:50\u201360","journal-title":"Am J Kidney Dis"},{"key":"4476_CR72","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-015-0094-5","volume":"16","author":"H Trachtman","year":"2015","unstructured":"Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS (2015) Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol 16:111","journal-title":"BMC Nephrol"},{"key":"4476_CR73","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","volume":"2","author":"F Vincenti","year":"2017","unstructured":"Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J, Focal Segmental Glomerulosclerosis Study Group (2017) A phase 2, double-blind, placebo-controlled, randomized study of Fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. Kidney Int Rep 2:800\u2013810","journal-title":"Kidney Int Rep"},{"key":"4476_CR74","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/ndt\/gfp278","volume":"24","author":"E De Smet","year":"2009","unstructured":"De Smet E, Rioux JP, Ammann H, Deziel C, Querin S (2009) FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 24:2938\u20132940","journal-title":"Nephrol Dial Transplant"},{"key":"4476_CR75","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1744-9987.2011.00949.x","volume":"15","author":"M Kopac","year":"2011","unstructured":"Kopac M, Meglic A, Rus RR (2011) Partial remission of resistant nephrotic syndrome after oral galactose therapy. Ther Apher Dial 15:269\u2013272","journal-title":"Ther Apher Dial"},{"key":"4476_CR76","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00467-013-2539-z","volume":"28","author":"K Sgambat","year":"2013","unstructured":"Sgambat K, Banks M, Moudgil A (2013) Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol 28:2131\u20132135","journal-title":"Pediatr Nephrol"},{"key":"4476_CR77","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2215\/CJN.02840313","volume":"8","author":"J Hogan","year":"2013","unstructured":"Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA (2013) Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol 8:2072\u20132081","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.12688\/f1000research.10165.1","volume":"6","author":"A Bierzynska","year":"2017","unstructured":"Bierzynska A, Saleem M (2017) Recent advances in understanding and treating nephrotic syndrome. F1000Res 6:121","journal-title":"F1000Res"},{"key":"4476_CR79","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","volume":"29","author":"H Trachtman","year":"2018","unstructured":"Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R, DUET Study Group (2018) DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 29:2745\u20132754","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/ijn.IJN_330_17","volume":"29","author":"M Nandi","year":"2019","unstructured":"Nandi M, Mandal SK, Samanta M, Majhi A, Das MK (2019) Efficacy of mycophenolate mofetil as a remission maintaining agent in idiopathic childhood nephrotic syndrome. Indian J Nephrol 29:34\u201341","journal-title":"Indian J Nephrol"},{"key":"4476_CR81","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00467-009-1356-x","volume":"25","author":"VR de Mello","year":"2010","unstructured":"de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SP, de Andrade OV, Guidoni EB, Scheffer DK, Martini Filho D, Toporovski J, Benini V (2010) Mycophenolate mofetil in children with steroid\/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol 25:453\u2013460","journal-title":"Pediatr Nephrol"},{"key":"4476_CR82","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5301\/JN.2011.6327","volume":"24","author":"TT Gargah","year":"2011","unstructured":"Gargah TT, Lakhoua MR (2011) Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol 24:203\u2013207","journal-title":"J Nephrol"},{"key":"4476_CR83","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, Tonshoff B, Hoyer P, Querfeld U, Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie (GPN) (2013) Mycophenolate mofetil versus cyclosporin a in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24:1689\u20131697","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR84","first-page":"346","volume":"6","author":"A Nickavar","year":"2012","unstructured":"Nickavar A, Safarzadeh AE, Sotoudeh K, Otukesh H, Hooman N (2012) Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children. Iran J Kidney Dis 6:346\u2013349","journal-title":"Iran J Kidney Dis"},{"key":"4476_CR85","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s00467-004-1778-4","volume":"20","author":"T Ulinski","year":"2005","unstructured":"Ulinski T, Dubourg L, Said MH, Parchoux B, Ranchin B, Cochat P (2005) Switch from cyclosporine a to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20:482\u2013485","journal-title":"Pediatr Nephrol"},{"key":"4476_CR86","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1442-200X.2007.02487.x","volume":"49","author":"M Okada","year":"2007","unstructured":"Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T (2007) Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 49:933\u2013937","journal-title":"Pediatr Int"},{"key":"4476_CR87","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2015-0486","volume":"136","author":"B Basu","year":"2015","unstructured":"Basu B, Mahapatra TK, Mondal N (2015) Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics 136:e132\u2013e139","journal-title":"Pediatrics"},{"key":"4476_CR88","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.kint.2017.08.011","volume":"93","author":"MP Gruppen","year":"2018","unstructured":"Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, Massella L, Emma F, Niaudet P, Cornelissen EAM, Schurmans T, Raes A, van de Walle J, van Dyck M, Gulati A, Bagga A, Davin JC (2018) A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int 93:510\u2013518","journal-title":"Kidney Int"},{"key":"4476_CR89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.kint.2018.10.008","volume":"95","author":"M Vivarelli","year":"2019","unstructured":"Vivarelli M, Emma F (2019) Levamisole for children with nephrotic syndrome: new evidence for the use of an \u201cold\u201d drug. Kidney Int 95:25\u201328","journal-title":"Kidney Int"},{"key":"4476_CR90","doi-asserted-by":"crossref","unstructured":"Muhlig AK, Lee JY, Kemper MJ, Kronbichler A, Yang JW, Lee JM, Shin JI, Oh J (2019) Levamisole in children with idiopathic nephrotic syndrome: clinical efficacy and pathophysiological aspects. J Clin Med 8(6)","DOI":"10.3390\/jcm8060860"},{"key":"4476_CR91","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1042\/CS20140749","volume":"128","author":"L Jiang","year":"2015","unstructured":"Jiang L, Dasgupta I, Hurcombe JA, Colyer HF, Mathieson PW, Welsh GI (2015) Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into mechanisms of action via direct action on the kidney podocyte. Clin Sci (Lond) 128:883\u2013893","journal-title":"Clin Sci (Lond)"},{"key":"4476_CR92","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00467-005-1968-8","volume":"20","author":"EM Hodson","year":"2005","unstructured":"Hodson EM, Craig JC, Willis NS (2005) Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 20:1523\u20131530","journal-title":"Pediatr Nephrol"},{"key":"4476_CR93","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.kint.2018.08.039","volume":"95","author":"A Sinha","year":"2019","unstructured":"Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A (2019) Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney Int 95:210\u2013218","journal-title":"Kidney Int"},{"key":"4476_CR94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s004670050487","volume":"12","author":"K Tenbrock","year":"1998","unstructured":"Tenbrock K, Muller-Berghaus J, Fuchshuber A, Michalk D, Querfeld U (1998) Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome. Pediatr Nephrol 12:459\u2013462","journal-title":"Pediatr Nephrol"},{"key":"4476_CR95","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/0886022X.2018.1489287","volume":"40","author":"L Liu","year":"2018","unstructured":"Liu L, Yang L, Chang B, Zhang J, Guo Y, Yang X (2018) The protective effects of rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway. Ren Fail 40:492\u2013497","journal-title":"Ren Fail"},{"key":"4476_CR96","first-page":"321","volume":"32","author":"M Liern","year":"2012","unstructured":"Liern M, De Reyes V, Fayad A, Vallejo G (2012) Use of sirolimus in patients with primary steroid-resistant nephrotic syndrome. Nefrologia 32:321\u2013328","journal-title":"Nefrologia"},{"key":"4476_CR97","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1681\/ASN.2016050519","volume":"28","author":"S Zschiedrich","year":"2017","unstructured":"Zschiedrich S, Bork T, Liang W, Wanner N, Eulenbruch K, Munder S, Hartleben B, Kretz O, Gerber S, Simons M, Viau A, Burtin M, Wei C, Reiser J, Herbach N, Rastaldi MP, Cohen CD, Tharaux PL, Terzi F, Walz G, Godel M, Huber TB (2017) Targeting mTOR signaling can prevent the progression of FSGS. J Am Soc Nephrol 28:2144\u20132157","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR98","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2008.12.024","volume":"54","author":"G Tsagalis","year":"2009","unstructured":"Tsagalis G, Psimenou E, Iliadis A, Nakopoulou L, Laggouranis A (2009) Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases. Am J Kidney Dis 54:340\u2013344","journal-title":"Am J Kidney Dis"},{"key":"4476_CR99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2215\/CJN.00120605","volume":"1","author":"JA Tumlin","year":"2006","unstructured":"Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A (2006) A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 1:109\u2013116","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/j.ajkd.2006.10.020","volume":"49","author":"ME Cho","year":"2007","unstructured":"Cho ME, Hurley JK, Kopp JB (2007) Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 49:310\u2013317","journal-title":"Am J Kidney Dis"},{"key":"4476_CR101","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/08860220500198623","volume":"27","author":"K El-Reshaid","year":"2005","unstructured":"El-Reshaid K, El-Reshaid W, Madda J (2005) Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis. Ren Fail 27:523\u2013530","journal-title":"Ren Fail"},{"key":"4476_CR102","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1093\/ndt\/gfm366","volume":"22","author":"J Ballarin","year":"2007","unstructured":"Ballarin J, Poveda R, Ara J, Perez L, Calero F, Grinyo JM, Romero R (2007) Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant 22:3196\u20133201","journal-title":"Nephrol Dial Transplant"},{"key":"4476_CR103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000357355","volume":"4","author":"J Kim","year":"2014","unstructured":"Kim J, Patnaik N, Chorny N, Frank R, Infante L, Sethna C (2014) Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience. Nephron Extra 4:8\u201317","journal-title":"Nephron Extra"},{"key":"4476_CR104","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00467-008-1033-5","volume":"24","author":"E Oki","year":"2009","unstructured":"Oki E, Tsuruga K, Kudo M, Tsugawa K, Suzuki K, Tanaka H (2009) A novel multidrug therapy for difficult cyclosporine-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 24:873\u2013875","journal-title":"Pediatr Nephrol"},{"key":"4476_CR105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ped.12498","volume":"57","author":"S Hibino","year":"2015","unstructured":"Hibino S, Uemura O, Nagai T, Yamakawa S, Iwata N, Ito H, Nakano M, Tanaka K (2015) Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol. Pediatr Int 57:85\u201391","journal-title":"Pediatr Int"},{"key":"4476_CR106","doi-asserted-by":"crossref","first-page":"930965","DOI":"10.4061\/2011\/930965","volume":"2011","author":"AA Nikibakhsh","year":"2011","unstructured":"Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA (2011) Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. Int J Nephrol 2011:930965","journal-title":"Int J Nephrol"},{"key":"4476_CR107","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","volume":"27","author":"J Gellermann","year":"2012","unstructured":"Gellermann J, Ehrich JH, Querfeld U (2012) Sequential maintenance therapy with cyclosporin a and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 27:1970\u20131978","journal-title":"Nephrol Dial Transplant"},{"key":"4476_CR108","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00467-006-0294-0","volume":"22","author":"S Fujinaga","year":"2007","unstructured":"Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K (2007) A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71\u201376","journal-title":"Pediatr Nephrol"},{"key":"4476_CR109","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3:85ra46","journal-title":"Sci Transl Med"},{"key":"4476_CR110","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00467-017-3746-9","volume":"33","author":"K Iijima","year":"2018","unstructured":"Iijima K, Sako M, Kamei K, Nozu K (2018) Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol 33:1449\u20131455","journal-title":"Pediatr Nephrol"},{"key":"4476_CR111","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fped.2019.00313","volume":"7","author":"R Topaloglu","year":"2019","unstructured":"Topaloglu R, Gulhan B, Celegen K, Inozu M, Hayran M, Duzova A, Ozaltin F (2019) Rituximab for children with difficult-to-treat nephrotic syndrome: its effects on disease progression and growth. Front Pediatr 7:313","journal-title":"Front Pediatr"},{"key":"4476_CR112","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2015","unstructured":"Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A (2015) Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 30:96\u2013106","journal-title":"Nephrol Dial Transplant"},{"key":"4476_CR113","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K (2013) Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 28:257\u2013264","journal-title":"Pediatr Nephrol"},{"key":"4476_CR114","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","volume":"53","author":"U Fogueri","year":"2019","unstructured":"Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS (2019) Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother 53:357\u2013363","journal-title":"Ann Pharmacother"},{"key":"4476_CR115","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","volume":"5","author":"FC Fervenza","year":"2010","unstructured":"Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC, Mayo Nephrology Collaborative Group (2010) Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5:2188\u20132198","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR116","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","volume":"14","author":"B Seitz-Polski","year":"2019","unstructured":"Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, Ronco P, Esnault VLM (2019) High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol 14:1173\u20131182","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR117","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K (2017) Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 21:193\u2013202","journal-title":"Clin Exp Nephrol"},{"key":"4476_CR118","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","volume":"16","author":"A Kronbichler","year":"2017","unstructured":"Kronbichler A, Windpessl M, Pieringer H, Jayne DRW (2017) Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev 16:633\u2013643","journal-title":"Autoimmun Rev"},{"key":"4476_CR119","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5414\/CN108835","volume":"85","author":"S Fujinaga","year":"2016","unstructured":"Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T (2016) Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol 85:340\u2013345","journal-title":"Clin Nephrol"},{"key":"4476_CR120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ndt\/gfu258","volume":"30","author":"K Kamei","year":"2015","unstructured":"Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura M, Ito S (2015) Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant 30:91\u201396","journal-title":"Nephrol Dial Transplant"},{"key":"4476_CR121","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bcp.13548","volume":"84","author":"A Bonanni","year":"2018","unstructured":"Bonanni A, Calatroni M, D\u2019Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84:1238\u20131249","journal-title":"Br J Clin Pharmacol"},{"key":"4476_CR122","doi-asserted-by":"crossref","first-page":"e13175","DOI":"10.1111\/petr.13175","volume":"22","author":"J Bernard","year":"2018","unstructured":"Bernard J, Bruel A, Allain-Launay E, Dantal J, Roussey G (2018) Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome. Pediatr Transplant 22:e13175","journal-title":"Pediatr Transplant"},{"key":"4476_CR123","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41581-018-0037-z","volume":"14","author":"R Novelli","year":"2018","unstructured":"Novelli R, Benigni A, Remuzzi G (2018) The role of B7-1 in proteinuria of glomerular origin. Nat Rev Nephrol 14:589\u2013596","journal-title":"Nat Rev Nephrol"},{"key":"4476_CR124","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMc1400502","volume":"370","author":"A Benigni","year":"2014","unstructured":"Benigni A, Gagliardini E, Remuzzi G (2014) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 370:1261\u20131263","journal-title":"N Engl J Med"},{"key":"4476_CR125","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1681\/ASN.2015091002","volume":"27","author":"M Delville","year":"2016","unstructured":"Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, Olagne J, Nguyen C, Deschenes G, Moulin B, Delahousse M, Kesler-Roussey G, Beaudreuil S, Martinez F, Rabant M, Grimbert P, Gallazzini M, Terzi F, Legendre C, Canaud G (2016) B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS. J Am Soc Nephrol 27:2520\u20132527","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR126","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00467-006-0096-4","volume":"21","author":"Z Yi","year":"2006","unstructured":"Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ (2006) Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 21:967\u2013972","journal-title":"Pediatr Nephrol"},{"key":"4476_CR127","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00467-008-1026-4","volume":"24","author":"NA Soliman","year":"2009","unstructured":"Soliman NA, Francis M, Heeringa SF, Chernin G (2009) Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade? Pediatr Nephrol 24:1065\u20131070","journal-title":"Pediatr Nephrol"},{"key":"4476_CR128","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ekir.2017.02.019","volume":"2","author":"R Komers","year":"2017","unstructured":"Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, Shih A, Trachtman H (2017) Efficacy and safety of sparsentan compared with Irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney Int Rep 2:654\u2013664","journal-title":"Kidney Int Rep"},{"key":"4476_CR129","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.trsl.2008.04.001","volume":"151","author":"VJ Savin","year":"2008","unstructured":"Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151:288\u2013292","journal-title":"Transl Res"},{"key":"4476_CR130","first-page":"91","volume":"12","author":"AS Bomback","year":"2011","unstructured":"Bomback AS, Radhakrishnan J (2011) Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med 12:91\u201396","journal-title":"Discov Med"},{"key":"4476_CR131","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/IJNRD.S74349","volume":"8","author":"P Lorusso","year":"2015","unstructured":"Lorusso P, Bottai A, Mangione E, Innocenti M, Cupisti A, Egidi MF (2015) Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study. Int J Nephrol Renovasc Dis 8:7\u201312","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"4476_CR132","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2215\/CJN.06890618","volume":"13","author":"CS Wang","year":"2018","unstructured":"Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, Benfield MR, Hidalgo G, Srivastava T, Lo M, Yadin O, Mathias R, Araya CE, Khalid M, Orjuela A, Zaritsky J, Al-Akash S, Kamel M, Greenbaum LA (2018) Adrenocorticotropic hormone for childhood nephrotic syndrome: the ATLANTIS randomized trial. Clin J Am Soc Nephrol 13:1859\u20131865","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR133","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/j.ajkd.2018.12.025","volume":"74","author":"DM Hartung","year":"2019","unstructured":"Hartung DM, Johnston K, Deodhar A, Bourdette DN, Cohen DM (2019) Repository corticotropin versus glucocorticoid for nephrotic syndrome: when will we see the evidence? Am J Kidney Dis 74:256\u2013262","journal-title":"Am J Kidney Dis"},{"key":"4476_CR134","doi-asserted-by":"crossref","first-page":"e180482","DOI":"10.1001\/jamanetworkopen.2018.0482","volume":"1","author":"DM Hartung","year":"2018","unstructured":"Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN (2018) Industry payments to physician specialists who prescribe repository corticotropin. JAMA Netw Open 1:e180482","journal-title":"JAMA Netw Open"},{"key":"4476_CR135","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jamainternmed.2017.3631","volume":"177","author":"DM Hartung","year":"2017","unstructured":"Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN (2017) Trends and characteristics of US Medicare spending on repository corticotropin. JAMA Intern Med 177:1680\u20131682","journal-title":"JAMA Intern Med"},{"key":"4476_CR136","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3389\/fimmu.2017.00962","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Peng Y, Fan Z, Zhao K, Chen X, Lin R, Sun J, Wang G, Xiang A, Liu Q (2017) Mesenchymal stem cells may ameliorate nephrotic syndrome post-allogeneic hematopoietic stem cell transplantation-case report. Front Immunol 8:962","journal-title":"Front Immunol"},{"key":"4476_CR137","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.biologicals.2013.09.004","volume":"41","author":"M Belingheri","year":"2013","unstructured":"Belingheri M, Lazzari L, Parazzi V, Groppali E, Biagi E, Gaipa G, Giordano R, Rastaldi MP, Croci D, Biondi A, Rebulla P, Edefonti A, Ghio L (2013) Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis. Biologicals 41:439\u2013445","journal-title":"Biologicals"},{"key":"4476_CR138","first-page":"16","volume":"2","author":"SK Mallipattu","year":"2015","unstructured":"Mallipattu SK, He JC (2015) The beneficial role of retinoids in glomerular disease. Front Med (Lausanne) 2:16","journal-title":"Front Med (Lausanne)"},{"key":"4476_CR139","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10157-017-1449-y","volume":"22","author":"Y Harita","year":"2018","unstructured":"Harita Y (2018) Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis. Clin Exp Nephrol 22:491\u2013500","journal-title":"Clin Exp Nephrol"},{"key":"4476_CR140","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/ng1918","volume":"38","author":"B Hinkes","year":"2006","unstructured":"Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Muller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O\u2019Toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nurnberg P, Hildebrandt F (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38:1397\u20131405","journal-title":"Nat Genet"},{"key":"4476_CR141","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00467-009-1211-0","volume":"24","author":"M Malina","year":"2009","unstructured":"Malina M, Cinek O, Janda J, Seeman T (2009) Partial remission with cyclosporine a in a patient with nephrotic syndrome due to NPHS2 mutation. Pediatr Nephrol 24:2051\u20132053","journal-title":"Pediatr Nephrol"},{"key":"4476_CR142","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00431-010-1278-4","volume":"170","author":"AM Wasilewska","year":"2011","unstructured":"Wasilewska AM, Kuroczycka-Saniutycz E, Zoch-Zwierz W (2011) Effect of cyclosporin a on proteinuria in the course of glomerulopathy associated with WT1 mutations. Eur J Pediatr 170:389\u2013391","journal-title":"Eur J Pediatr"},{"key":"4476_CR143","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1093\/ndt\/gfn271","volume":"23","author":"SF Heeringa","year":"2008","unstructured":"Heeringa SF, Vlangos CN, Chernin G, Hinkes B, Gbadegesin R, Liu J, Hoskins BE, Ozaltin F, Hildebrandt F, Members of the APN Study Group (2008) Thirteen novel NPHS1 mutations in a large cohort of children with congenital nephrotic syndrome. Nephrol Dial Transplant 23:3527\u20133533","journal-title":"Nephrol Dial Transplant"},{"key":"4476_CR144","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/ndt\/gfp229","volume":"24","author":"S Santin","year":"2009","unstructured":"Santin S, Ars E, Rossetti S, Salido E, Silva I, Garcia-Maset R, Gimenez I, Ruiz P, Mendizabal S, Luciano Nieto J, Pena A, Camacho JA, Fraga G, Cobo MA, Bernis C, Ortiz A, de Pablos AL, Sanchez-Moreno A, Pintos G, Mirapeix E, Fernandez-Llama P, Ballarin J, Torra R, Group FS, Zamora I, Lopez-Hellin J, Madrid A, Ventura C, Vilalta R, Espinosa L, Garcia C, Melgosa M, Navarro M, Gimenez A, Cots JV, Alexandra S, Caramelo C, Egido J, San Jose MD, de la Cerda F, Sala P, Raspall F, Vila A, Daza AM, Vazquez M, Ecija JL, Espinosa M, Justa ML, Poveda R, Aparicio C, Rosell J, Muley R, Montenegro J, Gonzalez D, Hidalgo E, de Frutos DB, Trillo E, Gracia S, de los Rios FJ (2009) TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant 24:3089\u20133096","journal-title":"Nephrol Dial Transplant"},{"key":"4476_CR145","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00467-017-3819-9","volume":"33","author":"G Dorval","year":"2018","unstructured":"Dorval G, Gribouval O, Martinez-Barquero V, Machuca E, Tete MJ, Baudouin V, Benoit S, Chabchoub I, Champion G, Chauveau D, Chehade H, Chouchane C, Cloarec S, Cochat P, Dahan K, Dantal J, Delmas Y, Deschenes G, Dolhem P, Durand D, Ekinci Z, El Karoui K, Fischbach M, Grunfeld JP, Guigonis V, Hachicha M, Hogan J, Hourmant M, Hummel A, Kamar N, Krummel T, Lacombe D, Llanas B, Mesnard L, Mohsin N, Niaudet P, Nivet H, Parvex P, Pietrement C, de Pontual L, Noble CP, Ribes D, Ronco P, Rondeau E, Sallee M, Tsimaratos M, Ulinski T, Salomon R, Antignac C, Boyer O (2018) Clinical and genetic heterogeneity in familial steroid-sensitive nephrotic syndrome. Pediatr Nephrol 33:473\u2013483","journal-title":"Pediatr Nephrol"},{"key":"4476_CR146","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1172\/JCI79504","volume":"125","author":"HY Gee","year":"2015","unstructured":"Gee HY, Zhang F, Ashraf S, Kohl S, Sadowski CE, Vega-Warner V, Zhou W, Lovric S, Fang H, Nettleton M, Zhu JY, Hoefele J, Weber LT, Podracka L, Boor A, Fehrenbach H, Innis JW, Washburn J, Levy S, Lifton RP, Otto EA, Han Z, Hildebrandt F (2015) KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest 125:2375\u20132384","journal-title":"J Clin Invest"},{"key":"4476_CR147","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ajhg.2014.04.010","volume":"94","author":"HY Gee","year":"2014","unstructured":"Gee HY, Ashraf S, Wan X, Vega-Warner V, Esteve-Rudd J, Lovric S, Fang H, Hurd TW, Sadowski CE, Allen SJ, Otto EA, Korkmaz E, Washburn J, Levy S, Williams DS, Bakkaloglu SA, Zolotnitskaya A, Ozaltin F, Zhou W, Hildebrandt F (2014) Mutations in EMP2 cause childhood-onset nephrotic syndrome. Am J Hum Genet 94:884\u2013890","journal-title":"Am J Hum Genet"},{"key":"4476_CR148","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","volume":"70","author":"CY Xing","year":"2006","unstructured":"Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW (2006) Direct effects of dexamethasone on human podocytes. Kidney Int 70:1038\u20131045","journal-title":"Kidney Int"},{"key":"4476_CR149","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine a. Nat Med 14:931\u2013938","journal-title":"Nat Med"},{"key":"4476_CR150","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2215\/CJN.01190210","volume":"5","author":"AK Buscher","year":"2010","unstructured":"Buscher AK, Kranz B, Buscher R, Hildebrandt F, Dworniczak B, Pennekamp P, Kuwertz-Broking E, Wingen AM, John U, Kemper M, Monnens L, Hoyer PF, Weber S, Konrad M (2010) Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 5:2075\u20132084","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR151","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2215\/CJN.07370715","volume":"11","author":"AK Buscher","year":"2016","unstructured":"Buscher AK, Beck BB, Melk A, Hoefele J, Kranz B, Bamborschke D, Baig S, Lange-Sperandio B, Jungraithmayr T, Weber LT, Kemper MJ, Tonshoff B, Hoyer PF, Konrad M, Weber S, German Pediatric Nephrology Association (GPN) (2016) Rapid response to Cyclosporin a and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 11:245\u2013253","journal-title":"Clin J Am Soc Nephrol"},{"key":"4476_CR152","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10545-014-9749-9","volume":"38","author":"MA Desbats","year":"2015","unstructured":"Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L (2015) Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. J Inherit Metab Dis 38:145\u2013156","journal-title":"J Inherit Metab Dis"},{"key":"4476_CR153","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/cge.12960","volume":"92","author":"M Gigante","year":"2017","unstructured":"Gigante M, Diella S, Santangelo L, Trevisson E, Acosta MJ, Amatruda M, Finzi G, Caridi G, Murer L, Accetturo M, Ranieri E, Ghiggeri GM, Giordano M, Grandaliano G, Salviati L, Gesualdo L (2017) Further phenotypic heterogeneity of CoQ10 deficiency associated with steroid resistant nephrotic syndrome and novel COQ2 and COQ6 variants. Clin Genet 92:224\u2013226","journal-title":"Clin Genet"},{"key":"4476_CR154","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1681\/ASN.2006080833","volume":"18","author":"F Diomedi-Camassei","year":"2007","unstructured":"Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, Emma F (2007) COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 18:2773\u20132780","journal-title":"J Am Soc Nephrol"},{"key":"4476_CR155","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1172\/JCI45693","volume":"121","author":"SF Heeringa","year":"2011","unstructured":"Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, Xie LX, Salviati L, Hurd TW, Vega-Warner V, Killen PD, Raphael Y, Ashraf S, Ovunc B, Schoeb DS, McLaughlin HM, Airik R, Vlangos CN, Gbadegesin R, Hinkes B, Saisawat P, Trevisson E, Doimo M, Casarin A, Pertegato V, Giorgi G, Prokisch H, Rotig A, Nurnberg G, Becker C, Wang S, Ozaltin F, Topaloglu R, Bakkaloglu A, Bakkaloglu SA, Muller D, Beissert A, Mir S, Berdeli A, Varpizen S, Zenker M, Matejas V, Santos-Ocana C, Navas P, Kusakabe T, Kispert A, Akman S, Soliman NA, Krick S, Mundel P, Reiser J, Nurnberg P, Clarke CF, Wiggins RC, Faul C, Hildebrandt F (2011) COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 121:2013\u20132024","journal-title":"J Clin Invest"},{"key":"4476_CR156","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1172\/JCI69000","volume":"123","author":"S Ashraf","year":"2013","unstructured":"Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, Fang H, Song X, Cattran DC, Avila-Casado C, Paterson AD, Nitschke P, Bole-Feysot C, Cochat P, Esteve-Rudd J, Haberberger B, Allen SJ, Zhou W, Airik R, Otto EA, Barua M, Al-Hamed MH, Kari JA, Evans J, Bierzynska A, Saleem MA, Bockenhauer D, Kleta R, El Desoky S, Hacihamdioglu DO, Gok F, Washburn J, Wiggins RC, Choi M, Lifton RP, Levy S, Han Z, Salviati L, Prokisch H, Williams DS, Pollak M, Clarke CF, Pei Y, Antignac C, Hildebrandt F (2013) ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 123:5179\u20135189","journal-title":"J Clin Invest"},{"key":"4476_CR157","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1056\/NEJMc0800582","volume":"358","author":"G Montini","year":"2008","unstructured":"Montini G, Malaventura C, Salviati L (2008) Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 358:2849\u20132850","journal-title":"N Engl J Med"},{"key":"4476_CR158","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00467-017-3657-9","volume":"32","author":"E Park","year":"2017","unstructured":"Park E, Kang HG, Choi YH, Lee KB, Moon KC, Jeong HJ, Nagata M, Cheong HI (2017) Focal segmental glomerulosclerosis and medullary nephrocalcinosis in children with ADCK4 mutations. Pediatr Nephrol 32:1547\u20131554","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-020-04476-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T22:29:56Z","timestamp":1722464996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-020-04476-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":158,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4476"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04476-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"7 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}